版本:
中国

BRIEF-Neurocrine Bio's Ingrezza fails study in pedriatric Tourette's patients

May 23 Neurocrine Biosciences Inc

* Neurocrine announces phase ii results of vmat2 inhibitor ingrezza® for treatment of tourette syndrome

* Neurocrine biosciences inc- study did not meet its primary endpoint

* Neurocrine biosciences inc- there were a total of four discontinuations due to adverse events, two in each of placebo and ingrezza arms in study

* Neurocrine biosciences inc- company is also conducting an open-label, fixed-dose study of ingrezza in up to 180 subjects with tourette syndrome Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐